Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Amiodarone-induced thyroid dysfunction associated with cumulative dose.

Marcel L Bouvy¹, Eibert R Heerdink, Arno W Hoes

¹Department of Pharmacoepidemiology and Pharmacotherapy, Utrecht Institute for Pharmaceutical Sciences (UIPS), PO Box 80082, 3508 TB Utrecht, The Netherlands. m.bouvy@pharm.uu.nl

Pharmacoepidemiology and Drug Safety

|December 5, 2002

Summary

Amiodarone significantly increases the risk of thyroid disorders, including hyperthyroidism and hypothyroidism. Higher cumulative doses of amiodarone correlate with a greater risk of developing these thyroid conditions.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

The Value of Warning Signs From the WHO 2009 Dengue Classification in Detecting Severe Dengue in Children.

The Pediatric infectious disease journal·2024

Same author

[2023 Focused update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure].

Giornale italiano di cardiologia (2006)·2024

Same author

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC.

European journal of heart failure·2024

Same author

Diagnostic yield of a proactive strategy for early detection of cardiovascular disease versus usual care in adults with type 2 diabetes or chronic obstructive pulmonary disease in primary care in the Netherlands (RED-CVD): a multicentre, pragmatic, cluster-randomised, controlled trial.

The Lancet. Public health·2023

Same author

Safety of Switching From a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients With Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial.

Circulation·2023

Same author

2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.

European heart journal·2023

Area of Science:

Cardiology
Endocrinology
Pharmacology

Background:

Amiodarone is a widely used anti-arrhythmic medication.
Thyroid dysfunction is a known potential side effect of amiodarone therapy.
Risk stratification for amiodarone-induced thyroid disorder requires further investigation.

Purpose of the Study:

To determine the risk of thyroid disorder in patients initiating amiodarone treatment.
To quantify the association between amiodarone use and the incidence of hyperthyroidism and hypothyroidism.

Main Methods:

A nested case-control study was conducted within a cohort of 5522 patients starting an anti-arrhythmic drug.
Cases were defined as patients developing hyperthyroidism or hypothyroidism after amiodarone initiation.

Related Experiment Videos

Controls were matched patients who did not develop thyroid disease.

Main Results:

Amiodarone users showed significantly higher odds of hyperthyroidism (OR 6.3) and hypothyroidism (OR 6.6) compared to other anti-arrhythmics.
Cumulative amiodarone doses exceeding 144g were associated with a substantially increased risk of hyperthyroidism (OR 12.9).
A dose-response relationship was observed, though less pronounced for hypothyroidism.

Conclusions:

Amiodarone is associated with a notable increased risk of thyroid disorders.
Higher cumulative doses of amiodarone amplify the risk of developing thyroid dysfunction.
Clinicians must remain vigilant for thyroid disorders in patients treated with amiodarone, even with long-term use.